Shi Ruoran, Yu Fazheng, Hu Xueyu, Liu Yan, Jin Yuanyuan, Ren Honglin, Lu Shiying, Guo Jian, Chang Jiang, Li Yansong, Liu Zengshan, Wang Xiaoxu, Hu Pan
State Key Laboratory for Zoonotic Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, College of Veterinary Medicine, Jilin University, Changchun 130062, China.
Institute of Special Animal and Plant Sciences of Chinese Academy of Agricultural Sciences, Changchun 130112, China.
Foods. 2023 Feb 20;12(4):897. doi: 10.3390/foods12040897.
Inflammatory bowel disease (IBD) is a specific immune-associated intestinal disease. At present, the conventional treatment for patients is not ideal. Probiotics are widely used in the treatment of IBD patients due to their ability to restore the function of the intestinal mucosal barrier effectively and safely. subsp. is a kind of probiotic that exists in the intestines of hosts and is considered to have good probiotic properties. In this study, we evaluated the therapeutic effect of subsp. SC-5 (SC-5) on dextran sulfate sodium (DSS)-induced colitis in C57BL/6J mice. We estimated the effect of SC-5 on the clinical symptoms of mice through a body weight change, colon length, and DAI score. The inhibitory effects of SC-5 on the levels of cytokine IL-1β, IL-6, and TNF-α were determined by ELISA. The protein expression levels of NF-κB, MAPK signaling pathway, and the tight junction proteins occludin, claudin-3, and ZO-1 were verified using Western Blot and immunofluorescence. 16S rRNA was used to verify the modulatory effect of SC-5 on the structure of intestinal microbiota in DSS-induced colitis mice. The results showed that SC-5 could alleviate the clinical symptoms of DSS-induced colitis mice, and significantly reduce the expression of pro-inflammatory cytokines in the colon tissue. It also attenuated the inflammatory response by inhibiting the protein expression of NF-κB and MAPK signaling pathways. SC-5 improved the integrity of the intestinal mucosal barrier by strengthening tight junction proteins. In addition, 16S rRNA sequencing demonstrated that SC-5 was effective in restoring intestinal flora balance, as well as in increasing the relative abundance and diversity of beneficial microbiota. These results indicated that SC-5 has the potential to be developed as a new probiotic candidate that prevents or alleviates IBD.
炎症性肠病（IBD）是一种特定的免疫相关肠道疾病。目前，针对患者的传统治疗并不理想。益生菌因其能够有效且安全地恢复肠道黏膜屏障功能而被广泛应用于IBD患者的治疗。 亚种是一种存在于宿主肠道中的益生菌，被认为具有良好的益生菌特性。在本研究中，我们评估了 亚种SC-5（SC-5）对葡聚糖硫酸钠（DSS）诱导的C57BL/6J小鼠结肠炎的治疗效果。我们通过体重变化、结肠长度和疾病活动指数（DAI）评分来评估SC-5对小鼠临床症状的影响。通过酶联免疫吸附测定（ELISA）确定SC-5对细胞因子白细胞介素-1β（IL-1β）、白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）水平的抑制作用。使用蛋白质免疫印迹法（Western Blot）和免疫荧光法验证核因子κB（NF-κB）、丝裂原活化蛋白激酶（MAPK）信号通路以及紧密连接蛋白闭合蛋白（occludin）、闭合蛋白-3（claudin-3）和紧密连接蛋白1（ZO-1）的蛋白质表达水平。使用16S核糖体RNA（16S rRNA）验证SC-5对DSS诱导的结肠炎小鼠肠道微生物群结构的调节作用。结果表明，SC-5可以减轻DSS诱导的结肠炎小鼠的临床症状，并显著降低结肠组织中促炎细胞因子的表达。它还通过抑制NF-κB和MAPK信号通路的蛋白质表达来减轻炎症反应。SC-5通过加强紧密连接蛋白来改善肠道黏膜屏障的完整性。此外，16S rRNA测序表明，SC-5在恢复肠道菌群平衡以及增加有益微生物群的相对丰度和多样性方面是有效的。这些结果表明，SC-5有潜力被开发成为一种预防或缓解IBD的新型益生菌候选物。
